Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Hong Kong ETF (EWH) vs Novavax Inc (NVAX) Price & Performance

iShares MSCI Hong Kong ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Hong Kong ETF vs Novavax Inc — how do they compare? iShares MSCI Hong Kong ETF trades at $22.45, while Novavax Inc trades at $7.93 (market cap $1.31B). The key difference: iShares MSCI Hong Kong ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

EWHNVAX
Sector
Broad Market / FactorHealth
52-Week High
$24.55$11.19
52-Week Low
$20.66$6.22
Market Cap
$1.31B
Enterprise Value
$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Hong Kong ETF

EWH, a US-listed stock tracking Hong Kong equities, trades at $22.465, down 1.47% over 24 hours. Technical indicators signal a bearish trend with moving averages in sell territory, though oscillators are neutral. The stock faces resistance at $23 and support at $22. Recent news highlights the Hang Seng Index's rebound, driven by technology sector gains, with EWH positioned to benefit from this momentum.

The outlook for EWH hinges on Hong Kong market performance, with potential upside from continued tech recovery and Asian market stability. Risks include regional volatility and macroeconomic pressures. Analysts show mixed sentiment, balancing technical bearishness with fundamental opportunities in the rebounding index.

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

About iShares MSCI Hong Kong ETF

EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.

Read more on EWH

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX